科倫博泰生物-B(06990.HK):收到根據與WINDWARD BIO AG關於SKB378/HBM9378/WIN378的許可協議以現金及股權支付的首付款
格隆匯5月23日丨科倫博泰生物-B(06990.HK)宣佈,根據該公告披露之許可協議條款,公司已自Windward Bio收到首付款,包括:(i)現金付款,該款項於2025年2月收到,及(ii)Windward Bio母公司的股權,該股權於獲得中國境內相關監管批準並滿足其他交割條件後在2025年5月完成交割。
SKB378/HBM9378/WIN378是公司與和鉑醫藥共同開發的項目,雙方平分全球權利。SKB378/HBM9378/WIN378是一種新型的重組全人源單克隆抗體(mAb),能有效結合TSLP配體,通過阻斷TSLP與TSLP受體的相互作用,抑制TSLP介導的信號通路。TSLP是一種經充分驗證的細胞因子,在包括哮喘和慢性阻塞性肺疾病(COPD)在內的多種免疫疾病的發生和進展中起關鍵作用,抑制TSLP在多種炎症表型中已顯示出獲益。SKB378/HBM9378/WIN378經過改良,達到延長半衰期及抑制作用因子的效果,並以皮下注射方式給藥。
於2025年1月,有關SKB378/HBM9378/WIN378用於治療慢性阻塞性肺疾病的IND申請獲國家藥品監督管理局(NMPA)批準。公司亦已完成於中國健康受試者中開展的用於治療中度及重度哮喘的一期臨牀試驗。我們的合作夥伴Windward Bio正準備二期試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.